152 related articles for article (PubMed ID: 24166764)
1. Secretory ranalexin produced in recombinant Pichia pastoris exhibits additive or synergistic bactericidal activity when used in combination with polymyxin B or linezolid against multi-drug resistant bacteria.
Aleinein RA; Schäfer H; Wink M
Biotechnol J; 2014 Jan; 9(1):110-9. PubMed ID: 24166764
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
Desbois AP; Gemmell CG; Coote PJ
Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
[TBL] [Abstract][Full Text] [Related]
3. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
Graham S; Coote PJ
J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and expression of ranalexin, a bioactive antimicrobial peptide from Rana catesbeiana in Escherichia coli and assessments of its biological activities.
Aleinein RA; Hamoud R; Schäfer H; Wink M
Appl Microbiol Biotechnol; 2013 Apr; 97(8):3535-43. PubMed ID: 23053091
[TBL] [Abstract][Full Text] [Related]
5. Recombinant antimicrobial peptide hPAB-β expressed in Pichia pastoris, a potential agent active against methicillin-resistant Staphylococcus aureus.
Chen Z; Wang D; Cong Y; Wang J; Zhu J; Yang J; Hu Z; Hu X; Tan Y; Hu F; Rao X
Appl Microbiol Biotechnol; 2011 Jan; 89(2):281-91. PubMed ID: 20857289
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus.
Xu-hong Y; Falagas ME; Dong W; Karageorgopoulos DE; De-feng L; Rui W
J Antibiot (Tokyo); 2014 May; 67(5):369-71. PubMed ID: 24517925
[TBL] [Abstract][Full Text] [Related]
7. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA).
Desbois AP; Lang S; Gemmell CG; Coote PJ
J Appl Microbiol; 2010 Feb; 108(2):723-30. PubMed ID: 19709343
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
[TBL] [Abstract][Full Text] [Related]
9. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
[TBL] [Abstract][Full Text] [Related]
10. High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus.
Zhang Y; Teng D; Mao R; Wang X; Xi D; Hu X; Wang J
Appl Microbiol Biotechnol; 2014 Jan; 98(2):681-94. PubMed ID: 23624708
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
[TBL] [Abstract][Full Text] [Related]
12. Design, expression, and characterization of a novel targeted plectasin against methicillin-resistant Staphylococcus aureus.
Mao R; Teng D; Wang X; Xi D; Zhang Y; Hu X; Yang Y; Wang J
Appl Microbiol Biotechnol; 2013 May; 97(9):3991-4002. PubMed ID: 23095942
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of a new recombinant antimicrobial peptide, MP1102, against methicillin-resistant Staphylococcus aureus.
Zhang Y; Teng D; Wang X; Mao R; Cao X; Hu X; Zong L; Wang J
Appl Microbiol Biotechnol; 2015 Aug; 99(15):6255-66. PubMed ID: 25620367
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia.
Ghiselli R; Giacometti A; Cirioni O; Orlando F; Mocchegiani F; Pacci AM; Scalise G; Saba V
J Surg Res; 2001 Oct; 100(2):183-8. PubMed ID: 11592790
[TBL] [Abstract][Full Text] [Related]
16. MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.
Desbois AP; Sattar A; Graham S; Warn PA; Coote PJ
J Antimicrob Chemother; 2013 Nov; 68(11):2569-75. PubMed ID: 23800902
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms.
Dosler S; Mataraci E
Peptides; 2013 Nov; 49():53-8. PubMed ID: 23988790
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of ovine-derived cathelicidins and other antimicrobials against Escherichia coli O157:H7 and Staphylococcus aureus 1056 MRSA.
van der Linden DS; Short D; Dittmann A; Yu PL
Biotechnol Lett; 2009 Aug; 31(8):1265-7. PubMed ID: 19396584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
